The significant miss on EPS could concern investors about profitability, potentially putting downward pressure on the stock. However, the substantial beat on sales estimates and the impressive year-over-year sales growth could signal strong demand for Inhibrx's products, potentially offsetting concerns about profitability in the short term. The mixed results make the short-term impact on the stock price uncertain, hence the neutral score.